LifeSci Advisors Publishes JAKAFI Survey Results

NEW YORK, Jan. 24, 2012 /PRNewswire/ -- LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has published an independent survey of 59 hematologists regarding their current and expected use of JAKAFI (ruxolitinib). JAKAFI is a selective Janus kinase 1 (JAK1) and JAK2 inhibitor developed and marketed in the US by Incyte Corporation and internationally by Novartis. The FDA approved the drug in November 2011 as a treatment for myelofibrosis (MF).

"Based on the results of our proprietary survey we believe that there are approximately 16,200 MF patients currently being treated in the US in academic/major referral and community practices," said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors.  "Overall, academic and community hematologists expect to treat 45% and 42.4% of the MF patients with JAKAFI, respectively. The survey suggests that JAKAFI should achieve peak sales between $600 and $700 million in the United States."

Dr. McDonald's full Survey Report is available to download at no cost at the LifeSci Advisors website, http://lifesciadvisors.com/marketresearch/.

About LifeSci Advisors:

LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.

Important Disclosures:

The research described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. The author of this report and other LifeSci Advisors' directors, officers, employees do not invest in the securities of the company that is the subject of this report described in this press release. LifeSci Advisors directors, officers, and employees currently do not own shares of Incyte Corporation, Inc. LifeSci Advisors has not been compensated by the company that is the subject of the report described. Please read each report's full disclosures and analyst background on the LSA website, http://lifesciadvisors.com/disclaimer/, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.

Contact:

Michael Rice
Office Phone: (646) 597-6979
Mobile Phone: (917) 282-3242
Email: [email protected]

SOURCE LifeSci Advisors, LLC